The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Autoinjectors, pens, and prefilled syringes: How Thermo Fisher Scientific is advancing self-administered therapies
Thermo Fisher Scientific’s scale- and platform-flexible autoinjector, pen injector, and prefilled syringe capabilities can help streamline your supply chain strategy for clinical trials.
For many patients participating in clinical trials, receiving treatment can feel like a burden. Traveling to an infusion center, taking time away from work and family, and spending hours managing logistics instead of focusing on health—it all adds up, quickly affecting the overall experience. That’s why self-administration is becoming more common across a wide range of therapies. It brings care closer to home and gives patients greater control over their treatment.
This video explores Thermo Fisher’s scale- and platform-flexible autoinjector, pen injector, and prefilled syringe capabilities—from manual to fully automated—which can help simplify your biologic development supply chain strategy. As you progress through clinical trial phases, Thermo Fisher can evolve with you, supporting your changing fill–finish needs—from vials in Phase I/II to prefilled syringes, pen injectors, and autoinjectors in Phase II/III and commercialization.
In the video, you’ll see how Thermo Fisher’s capabilities can support:
- Device assembly spanning clinical through commercial stages
- Right-sized equipment scaling to maximize operational efficiency
- Reduced program disruptions by minimizing cross-functional handoffs
- Accelerated timelines enabled by integrated, end-to-end capabilities
Watch to see how Thermo Fisher can support you across the biologics drug development and manufacturing lifecycle—helping therapies reach patients when and where they’re needed.